Last reviewed · How we verify
PLB1001
PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival.
PLB1001 is a small-molecule inhibitor that targets specific kinases involved in cancer cell proliferation and survival. Used for Acute myeloid leukemia (AML), Other hematologic malignancies.
At a glance
| Generic name | PLB1001 |
|---|---|
| Also known as | Bozitinib, Vebreltinib |
| Sponsor | Beijing Pearl Biotechnology Limited Liability Company |
| Drug class | Kinase inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PLB1001 is designed to inhibit key signaling pathways that drive tumor growth. The drug works by blocking kinase activity in cancer cells, disrupting their ability to proliferate and survive. It is being developed primarily for hematologic malignancies and solid tumors.
Approved indications
- Acute myeloid leukemia (AML)
- Other hematologic malignancies
Common side effects
- Myelosuppression
- Gastrointestinal toxicity
- Hepatotoxicity
Key clinical trials
- A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). (PHASE2, PHASE3)
- A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) (PHASE3)
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (PHASE2)
- Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI (PHASE1, PHASE2)
- Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure (PHASE3)
- Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. (PHASE2)
- Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC (PHASE2)
- A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLB1001 CI brief — competitive landscape report
- PLB1001 updates RSS · CI watch RSS
- Beijing Pearl Biotechnology Limited Liability Company portfolio CI